AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants

Recruitingn/aAges 18 Years - anyAllUniversity of L'Aquila
💬

In plain words

What the trial is, and whether it could suit you

The Advancing knowledge in ischemic Stroke PatiEnts on oRal Anticoagulants (ASPERA) study aims to investigate characteristics of ischemic stroke cases occurring in patients on oral anticoagulation for atrial fibrillation (AF) or other cardioembolic arrhythmias and to characterize short and long-term outcomes associated with different secondary prevention strategies to prevent stroke recurrences. The ASPERA study is a multicenter, observational, both retrospective and prospective real-world study involving acute ischemic stroke patients occurring on oral anticoagulation. The study will encompass a retrospective (ASPERA-R) and prospective (ASPERA-P) data collection. Patient will be recruited consecutively at different emergency services and stroke units worldwide. University of L'Aquila (UnivAQ) will be in charge of study coordination, data analysis and management. The duration of ASPERA-R

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥18 years at the time of the index ischemic stroke. * Confirmed diagnosis of ischemic stroke according to the World Health Organization (WHO) definition. * Availability of at least one neuroimaging exam (either a non-contrast computed tomography \[NCCT\] or magnetic resonance imaging \[MRI\] of the brain) demonstrating one or more ischemic lesions consistent with patient symptoms. * Ongoing oral anticoagulation at the time of the index ischemic stroke, defined as the last intake within 48 hours prior to stroke symptom onset for patients on direct oral anticoagulants (DOACs), or an international normalized ratio (INR) of ≥1.5 in patients on vitamin K antagonists (VKAs), regardless of the time elapsed between the last intake and stroke symptom onset. * Prior diagnosis of AF or other cardioembolic arrhythmias. Exclusion Criteria: * Symptoms not indicative of acute stroke (i.e., syncope, tonic or clonic activity, dizziness alone, confusion and amnesia alone, chronic or subacute development of focal neurological deficit). * Ongoing parenteral (intravenous or subcutaneous) anticoagulation at the time of the index event, including bridging with heparin in patients initiating VKA.
💊

What it tests

  • Not listed
📍

Where

47 sites
Department of Neurology, Sveti Duh University Hospital
Zagreb, Croatia
Copenhagen University Hospital, Bispebjerg Hospital
Copenhagen, Denmark
Neurology Department, Assiut University Hospitals
Asyut, Egypt
Neurology Department, Faculty of Medicine , Ain Shams University
Cairo, Egypt
Neurology Unit, Kobry Elkoba Medical Complex
Cairo, Egypt
Université Cote d'Azur UR2CA-URRIS, Unité Neurovasculaire, CHU Hôpital Pasteur 2
Nice, France
Department of Neurology, Charite, Berlin Germany and Center for Stroke Research (CSB)
Berlin, Germany
Department of Neurology, Martin-Luther-University of Halle-Wittenberg
Halle, Germany

…and 39 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy